Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
  • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/14—Antitussive agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
  • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
  • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
  • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
  • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
  • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
  • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring

Definitions

• the present invention relates to derivatives of meta-trifluoromethylphenyl-piperazine and their therapeutical use, notably in the region of the central nervous system and in the cardiovascular region.
• R 2 represents an alkyl group containing 2 to 6 carbon atoms or a cycloalkyl or cycloalkylalkyl group containing 5 to 8 carbon atoms, each of these groups being substituted by one or two hydroxy groups or an oxo group and, if desired, also by a 4-(m-trifluoromethylphenyl)-piperazino or 4-(3-trifluoromethyl-4-fluorophenyl)- piperazino group with the proviso that, when R 1 represents a hydrogen atom, R 2 does not represent a monohydroxyalkyl group,
• the invention comprises more particularly the compounds of the formula I wherein R 1 represents a hydrogen atom, and R 2 represents a 2,3-dihydroxypropyl, 2-hydroxycyclohexyl, 2-oxocyclohexylmethyl, 3-[4-(m-trifluoromethylphenyl)-piperazino]-2-hydroxypropyl, 2-oxo-cyclopentylmethyl, 2-hydroxy-cyclohexylmethyl, 3-[4-(m-trifluoromethylphenyl)-piperazino]-2-oxo-propyl, or 2-oxo-cycloheptylmethyl group, or R 1 represents a fluorine atom, and R 2 represents a 2-hydroxyethyl, 2-oxo-cyclohexylmethyl, 3-[4-(3-trifluoromethyl-4-fluoro-phenyl)-piperazino]-2-hydroxypropyl or 2,3-dihydroxypropyl group, as well as their pharmaceutically acceptable acid addition salts.
• the compounds of the invention may be prepared by reaction of a compound corresponding to the formula II ##STR3## (wherein R 1 represents a hydrogen or fluorine atom) with a halogenated and/or epoxy derivative of radical R 2 defined above, or with a derivative R 2 H (wherein R 2 carries an oxo group) and formaldehyde.
• R 1 represents a hydrogen or fluorine atom
• R 2 H represents a derivative of radical
• formaldehyde a compound corresponding to the formula II ##STR3## (wherein R 1 represents a hydrogen or fluorine atom)
• R 2 H wherein R 2 carries an oxo group
• N-m-Trifluoromethylphenylpiperazine (R 1 ⁇ H) has been described in British Patent Specification No. 948,767 and N-(3-trifluoromethyl-4-fluoro-phenyl)-piperazine in U.S. Pat. No. 3,637,705.
• the invention also provides pharmaceutical compositions comprising a compound of the formula I or a pharmaceutically acceptable acid addition salt thereof togther with a pharmaceutically acceptable carrier or diluent.
• the invention further provides a method of treating a human patient which method comprises administering to the patient a compound of the formula I or a pharmaceutically acceptable acid addition salt thereof.
• the hydroiodide is prepared by adding concentrated hydroiodic acid to a 10% solution of the base in isopropanol. The product is filtered and recrystallised from isopropanol. 13.9 g (55% yield) of white crystals are obtained. Melting Point: 156-157° (LJ 1142).
• a mixture of 14 g (60 mmoles) m-trifluoromethylphenyl-piperazine and 5.88 g (6 ml, 60 mmoles) cyclohexane oxide are heated for 4 hours at 145°.
• the product is cooled and subjected to chromatography over 200 g silica.
• the elution is carried out successively with methylene chloride, and then chloroform, progressively enriched with methanol.
• the hydrochloride is precipitated by addition of water.
• the product is filtered and recrystallised from a mixture of 1/3 ethanol to 2/3 water by volume. 46.5 g of the hydrochloride hemi-hydrate are obtained. Melting Point: 240°-245° (LJ 1145).
• the hydrochloride is placed in suspension in chloroform and, gradually and with strong agitation, N-sodium hydroxide is added. When all is dissolved, the solution is washed with water saturated with sodium chloride, dried and evaporated. There is obtained an oil whose I.R., N.M.R. and mass spectra are consistent with the proposed structure.
• the fumarate hemi-hydrate is prepared in propanol. (LJ 1152).
• the diphosphate is prepared in ethanol and recrystallised from ethanol. Melting Point : 190°-197° (LJ 1154).
• the base liberated with 0.1 N sodium hydroxide, is extracted with benzene. After drying and evaporation of solvent the I.R., N.M.R. and mass spectra are in accord with the proposed structure.
• the mixture is rinsed with ether, washed three times with saturated sodium bicarbonate solution.
• the product is dried, evaporated and subjected to chromatography over silica using as eluant methylene chloride and then chloroform enriched progressively with methanol.
• the I.R., N.M.R. and mass spectra of the base obtained are in accord with the proposed structure.
• the hydrochloride hydrate is prepared in ether by addition of hydrochloric ether. 6.17 g (yield 40%) are obtained. Melting Point: 260°-265° (LJ 1163). C 25 H 32 Cl 2 F 6 N 4 O 2 . Calculated %: C 49.59; H 5.32; N 9.25; Cl 11.71; Found %: C 49.20; H 5.60; N 9.20; Cl 11.19.
• the compounds of the invention have been subjected to pharmacological study.
• the compounds are administered in increasing doses (in arithmetic progression) to groups of five ⁇ SWISS, EOPS, NMRI/Han mice of the EVIC CEBA strain and having a mean weight of 22 g.
• the compounds are dissolved in distilled water, for oral administration they are suspended in 10% gum arabic solution (volume administered: 0.5 ml/22 g body weight).
• the LD 50's are calculated according to the method of KARBER and BEHRENS (B.) (Arch. Exp. Path. Pharmakol. 1935, 177, 379-388).
• the number of animals surviving in the different groups is definitively verified 15 days after administrating the compounds.
• mice 30 minutes after administration per os of the test compounds, the mice (12 per group) are installed in individual cages of a BOISSIER activity measuring cupboard (BOISSIER (J.R.), SIMON (P), Arch. Int. Pharmacodyn, 1965, 158, 212-221) and move about before two photoelectric cells placed according to the rectangular co-ordinates. Meters register the movements over 20 minutes. The results are expressed as percentages of variation of the motor activity compared with the control group of animals.
• BOISSIER J.R.
• SIMON P
• Arch. Int. Pharmacodyn 1971, 158, 212-221
• the results are expressed as percentages of variation of the motor activity compared with the control group of animals.
• mice The rectal temperature of mice (groups of 10 animals) is measured with the aid of an ELLAB thermocouple.
• the test compounds are then administered orally and the temperature taken 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours and 6 hours later.
• mice receive an injection of pentobarbital at a dose (50 mg/kg i.v.) which, in control animals which have only received administration vehicle (10% gum arabic solution), induces a sleep of about 30 to 60 minutes.
• administration vehicle 10% gum arabic solution
• the mean sleep time is calculated and the results are expressed as percentages of variation based on the control group.
• mice (groups of 10 animals)
• the results are expressed as percentages of the protection compared with a control group.
• amphetamine bitartrate is injected interperitioeally at a dose of 10 mg/kg (dose giving substantially 100% mortality) to mice in groups of 10 in boxes 12 ⁇ 18 ⁇ 13 cm. The number of animals surviving 24 hours after the amphetamine administration is noted.
• the different compounds studied reduce motor activity and body temperature, agility and motor co-ordination; they increase the narcosis of pentobarbital and oppose the convulsant effects of electric shock.
• the results are the reflection of a sedative, tranquillising and anxiety relieving effect.
• LJ 1144, 1160, 1161 and 1176 reduce the toxicity of amphetamine compounds, the absence of cataleptic effect does not permit the conclusion of a neuroleptic effect for the four compounds.
• the guinea pigs ⁇ of mean weight 400 g, unanaesthesised, are subjected to the tussigenic effect of aerosols of a 7.5% aqueous citric acid solution.
• the animals are placed one by one in a cylindrical chamber having at its two extremities two canals, one serving as entrance for the aerosol and the other as its exit.
• Each guinea pig is first submitted to a control test for 5 minutes. One hour later it receives the test compound. It is replaced in the chamber for 5 minutes, 1 hour after oral administration of the compound.
• the number of coughing attacks before and after administration is counted and the percentage inhibition is calculated.
• Table 3 shows that the test compounds possess valuable antitussive activity.
• LJ 1144, 1152, 1154, 1161, 1163 and 1176 are also active if not more active than codeine.
• Domenjoz (Arch. Exper. Path. Pharmakol. 1952, 215, 19-24,), which comprises obtaining coughing by stimulation of the superior larynx nerve, was used.
• a cannula having three branches is placed in the trachea. Two of the branches are connected to a device for registering intratracheal pressure (MERCURY gas pressure gauge connected to an RACIA polygraph)
• the third branch allows elimination of part of the respiratory volume.
• a cannula is placed in the femoral vein for administration of the test substances.
• the superior larynx nerve is isolated and the stimulation electrode (RACIA stimulator) is placed on the intact (unbound) nerve.
• the stimulation parameters are as follows: frequency: 5 cycles per sec, amplitude: 5 millisec, voltage: 4 to 6 volts, duration: 15 to 45 sec. (according to the sensitivity of the animal).
• the compound is then administered intravenously.
• the stimulation is then carried out every 5 minutes. If the compound reduces or suppresses the coughing the stimulation is continued until the reappearance of coughing to approximately the same degree as the initial coughing.
• results are expressed as a percentage reduction in the number of coughs. They are summarized in Table 4 and show that 4 compounds selected from the preceding test are equally active on coughing in cats, the effects of LJ 1152 and 1154 are comparable with those of codeine.
• the derivatives of the present invention are endowed with sedative and tranquillising and antitussive properties.
• Compounds of the invention may be administered orally, rectally and parenterally.
• posology is a function of the therapeutic indication and the nature of the compound concerned.
• An indicative standard of posology for an adult may comprise between 0.5 and 10 mg/kg orally and 0.5 to 5 mg parenterally.
• the preferred pharmaceutical forms are tablets, capsules, drinkable suspensions, suppositories, aerosols, injectable solutions, etc.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Pulmonology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9723745

Family Applications (1)

Country Status (14)

Cited By (9)

Families Citing this family (11)

Citations (6)

Family Cites Families (2)

• 1977
  • 1977-01-14 GB GB1539/77A patent/GB1560271A/en not_active Expired
  • 1977-12-26 FR FR7739188A patent/FR2377392A1/fr active Granted
• 1978
  • 1978-01-05 FI FI780034A patent/FI780034A/fi not_active Application Discontinuation
  • 1978-01-09 AU AU32290/78A patent/AU512266B2/en not_active Expired
  • 1978-01-09 ZA ZA00780124A patent/ZA78124B/xx unknown
  • 1978-01-10 NZ NZ186189A patent/NZ186189A/xx unknown
  • 1978-01-11 DE DE19782800954 patent/DE2800954A1/de active Pending
  • 1978-01-12 JP JP157778A patent/JPS5439085A/ja active Pending
  • 1978-01-13 ES ES465939A patent/ES465939A1/es not_active Expired
  • 1978-01-13 US US05/869,277 patent/US4203986A/en not_active Expired - Lifetime
  • 1978-05-12 BE BE187654A patent/BE867030A/xx unknown
  • 1978-05-12 IT IT7823355A patent/IT7823355A0/it unknown
  • 1978-06-01 SE SE7806466A patent/SE7806466L/xx unknown
  • 1978-07-12 LU LU79968A patent/LU79968A1/xx unknown

Patent Citations (6)

Also Published As

Similar Documents